PharmaShots | Incisive News in 3 Shots

Subscribe Now

biocon biologics

Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US

Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US

March 7, 2025

Biocon Biologics Launches Yesintek (Biosimilar, Stelara) in the US

Biocon Biologics Launches Yesintek (Biosimilar, Stelara) in the US

February 24, 2025

Biocon Biologics Reports the US FDA’s Approval of Yesintek (Biosimilar, Stelara)

Biocon Biologics Reports the US FDA’s Approval of Yesintek (Biosimilar, Stelara)

December 2, 2024

Biocon Biologics’ Yesafili (biosimilar, aflibercept) Receives EC’s Approval for Ophthalmic Conditions

Biocon Biologics’ Yesafili (biosimilar, aflibercept) Receives EC’s Approval for Ophthalmic Conditions

September 22, 2023

Biocon Biologics Receives EMA’s CHMP Positive Opinion of Yesafili (biosimilar, aflibercept)

Biocon Biologics Receives EMA’s CHMP Positive Opinion of Yesafili (biosimilar, aflibercept)

July 24, 2023

Biocon Biologics and its Partner Viatris Receive the Complete Response Letter from the US FDA for Bevacizumab Biosimilar

Biocon Biologics and its Partner Viatris Receive the Complete Response Letter from the US FDA for Bevacizumab Biosimilar

January 12, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us